Actionable identification of critical infections
The T2Bacteria® Panel, which is currently submitted for FDA clearance in the U.S. and CE Marked in the EU, identifies six of the most deadly and prevalent bacteria species that are often not covered by empiric therapy. The T2Bacteria RUO Panel is currently available for Research Use Only (RUO) in the U.S. As with the FDA-cleared T2Candida® Panel, the T2Bacteria Panel will provide species-specific results directly from whole blood and are available within hours of patient presentation.
Results direct from blood draw
Rapid detection and identification of sepsis-causing pathogens are critical for optimizing antimicrobial therapy to improve patient survival and substantially reduce healthcare costs. Together, the T2Bacteria Panel and the T2Candida Panel are the ONLY tests that can enable 95% of patients with bloodstream infections to receive targeted therapy within hours, when treatment has the most significant impact on patient outcomes.1,2
Rapidly detect and identify species, no blood culture required
Today, implementation of the T2Candida Panel in approximately 130 hospitals globally has shortened length of stay, reduced antimicrobial consumption and identified patients missed by blood culture.
The T2Bacteria Panel, which runs on the same FDA-cleared T2Dx® Instrument as the T2Candida Panel, is deigned to be used on patients presenting in the emergency department or with symptomatic inpatients. Independent studies have proven that rapid detection and treatment can reduce patient mortality by 50% or more, while reducing hospital and ICU length of stay by 3 to 7 days.3,4-9
Timely and accurate results to support clinical action
Initial empiric antimicrobial therapy effectively treats about 60% of all septic patients.10 By focusing on those pathogens that often do not respond to initial empiric therapy, results from the FDA-cleared T2Candida Panel and the T2Bacteria Panel, once commercially available, may enable the administration of effective therapy within hours of patient presentation and long before blood-culture-based results are available.
Impact of timely, effective sepsis treatment
- Decreased mortality rates3
Shortened length of stay
- 3 to 7 ICU days saved4-9
- 1 to 7 hospital days saved4-9
- Reduced use of antimicrobial drugs4-9
- Reduced healthcare spending; savings of ~$25,000 per positive patient4-9,11
- Improved healthcare quality metrics
The T2Bacteria Panel identifies ~90% of Gram Negative and ~70% of community-acquired infections seen in the Emergency Department.12,13